Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab govitecan in advanced extrapulmonary high-grade neuroendocrine neoplasms
ChiCTR2500108754Phase 2Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Sep 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab govitecan in neuroendocrine carcinoma (NEC), apudoma (NET) and mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Objective Response Rate. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
neuroendocrine carcinoma (NEC)apudoma (NET)mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN)
Beyond the preview
Go deeper on ChiCTR2500108754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108754.